However, molecular profiling, including attention to gene mutations common in these endometriosis-associated ovarian cancers (i.e., ARID1A, PIK3CA, CTNNB1, PTEN, and KRAS) and mutations common in high-grade serous (i.e., TP53), have allowed better molecular and biological distinction [176,177,178,179,180,181,182]. This evidence concerns the gene KRAS and ovarian cancer.